A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

NCT05259709 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor

Interventions

DRUG: 89Zr˗DFO˗REGN5054
DRUG: cemiplimab

Sponsor

Regeneron Pharmaceuticals